Compounders Research Compare

Viridian Therapeutics, Inc.(VRDN)

Biotechnology · Waltham, MA

$18.22-0.78 (-4.11%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Waltham, MA

252 employees

www.viridiantherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stephen F. Mahoney

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T21:18:39.207Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:18:39.207Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -3.53
Quote price: 18.22

FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

VRDN Earnings Yield Metrics

EARNINGS YIELD

N/A

VRDN Competitors' Earnings Yield

Viridian Therapeutics, Inc.

Current

Market Cap

$2.06B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Celldex Therapeutics, Inc.

Market Cap

$2.06B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alvotech

Market Cap

$2.08B

Earnings Yield

N/A

TTM Avg

3.77%

3Y Avg

3.77%

5Y Avg

3.77%

Vericel Corporation

Market Cap

$2.05B

Earnings Yield

1.17%

TTM Avg

0.84%

3Y Avg

0.48%

5Y Avg

0.48%

Progyny, Inc.

Market Cap

$2.03B

Earnings Yield

3.55%

TTM Avg

3.03%

3Y Avg

2.65%

5Y Avg

2.15%

BioCryst Pharmaceuticals, Inc.

Market Cap

$2.02B

Earnings Yield

N/A

TTM Avg

13.14%

3Y Avg

13.14%

5Y Avg

13.14%

SELLAS Life Sciences Group, Inc.

Market Cap

$2.11B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

UroGen Pharma Ltd.

Market Cap

$2.02B

Earnings Yield

N/A

TTM Avg

0.51%

3Y Avg

0.51%

5Y Avg

0.51%

Aurinia Pharmaceuticals Inc.

Market Cap

$2.02B

Earnings Yield

14.60%

TTM Avg

9.78%

3Y Avg

7.02%

5Y Avg

7.02%

Vera Therapeutics, Inc.

Market Cap

$2.11B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Viridian Therapeutics, Inc. (VRDN)	$2.06B	N/A	N/A	N/A	N/A
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.06B	N/A	N/A	N/A	N/A
Alvotech (ALVO)vs ›	$2.08B	N/A	3.77%	3.77%	3.77%
Vericel Corporation (VCEL)vs ›	$2.05B	1.17%	0.84%	0.48%	0.48%
Progyny, Inc. (PGNY)vs ›	$2.03B	3.55%	3.03%	2.65%	2.15%
BioCryst Pharmaceuticals, Inc. (BCRX)vs ›	$2.02B	N/A	13.14%	13.14%	13.14%
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.11B	N/A	N/A	N/A	N/A
UroGen Pharma Ltd. (URGN)vs ›	$2.02B	N/A	0.51%	0.51%	0.51%
Aurinia Pharmaceuticals Inc. (AUPH)vs ›	$2.02B	14.60%	9.78%	7.02%	7.02%
Vera Therapeutics, Inc. (VERA)vs ›	$2.11B	N/A	N/A	N/A	N/A

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics